Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic
Gal Rinott Mizrahi1, Isabella Williams1, Arun Azad2
1Department of Urology, The Royal Melbourne Hospital.
Purpose Of Review:
Neuroendocrine prostate cancer (NEPC) is a rare histologic subtype of prostate cancer with extremely aggressive clinical behaviour and very limited data regarding treatment options. This review is intended to relay new research advances in the understanding of the genetic and epigenetic aberrations underlying NEPC development and to review new targeted therapeutic options developed based on NEPC genetics.
Recent Findings:
Multiple genomic alterations and epigenetic regulators have been identified in NEPC development. Among these are amplifications of oncogenic transcriptional factors, changes in expression of cell surface markers and epigenetic alterations. This in turn has facilitated a number of new targeted therapies for NEPC that act via different mechanisms including catalytic inhibitors, immune-modulators and epigenetic modifiers. These targeted therapies are now being studied in different phases of clinical trials with some preliminary results showing efficacy.
Summary:
NEPC is a highly aggressive malignancy with currently lack of effective treatments. Considerable challenges still remains to improve clinical outcomes in NEPC; however, ongoing trials exploiting novel genetic and epigenetic alterations hold promise for patients suffering from this aggressive disease.
Insights
Neuroendocrine prostate cancer (NEPC) is aggressive, with new research identifying genetic and epigenetic drivers. Targeted therapies based on these findings show promise in ongoing clinical trials for this rare cancer.
Area of Science:
- Oncology
- Genetics
- Epigenetics
Background:
- Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer.
- Limited data exists regarding effective treatment options for NEPC.
Purpose of the Study:
- To review recent research on genetic and epigenetic aberrations in NEPC development.
- To discuss novel targeted therapeutic options emerging from NEPC genetics.
Main Methods:
- Review of current scientific literature on NEPC genetics and epigenetics.
- Analysis of emerging targeted therapies and their mechanisms of action.
- Examination of ongoing clinical trials and preliminary efficacy data.
Main Results:
- Multiple genomic alterations and epigenetic regulators identified in NEPC.
- Amplifications of oncogenic transcription factors and altered cell surface marker expression are key findings.
- New targeted therapies, including catalytic inhibitors, immune-modulators, and epigenetic modifiers, are under investigation.
Conclusions:
- NEPC is a challenging malignancy with unmet treatment needs.
- Ongoing clinical trials targeting novel genetic and epigenetic alterations offer hope for improved patient outcomes.
